J&J Consumer Leadership Reshuffle Continues
This article was originally published in The Tan Sheet
Johnson & Johnson continues reorganizing its consumer teams as the firm deals with several years of quality control problems in its McNeil Consumer Healthcare unit.
You may also be interested in...
J&J names pharma vet to lead McNeil
As the new head of Johnson & Johnson's beleaguered U.S. OTC business, Pat Mutchler takes on the burden of restoring the firm's reputation and manufacturing quality.
Firm has pending ANDAs for generic versions of McNeil's Rx Concerta (methylphenidare hydrochloride) extended-release tablets in 18, 27, 36 and 54 mg formulations. McNeil's exclusivity for the pediatric hyperactivity deficit disorder drug was set to expire March 17, and the firm has filed a citizen petition with FDA "that affects the timing of, and potentially the approval criteria for, ANDA approvals relating to generic Concerta," according to Andrx. McNeil put 300 sales reps behind the drug in 2000 (1"The Tan Sheet," April 24, 2000, In Brief)...